Imricor Medical Systems has officially started commercial operations in the United States after announcing Rady Children’s Hospital-San Diego as the first U.S. hospital customer for its NorthStar interventional magnetic resonance (iMR) mapping and guidance system. The agreement represents a major commercial milestone for the company as it transitions from regulatory approval and clinical development toward broader adoption of its radiation-free cardiac procedure technology.
The installation will allow Rady Children’s Hospital to establish a cardiac catheterisation program using real-time magnetic resonance guidance instead of conventional X-ray fluoroscopy. The move is expected to support the hospital’s long-term objective of developing a fully radiation-free pathway for pediatric cardiac procedures, including catheterisation, electrophysiology, and cardiac ablation.
The announcement follows a series of regulatory achievements by Imricor in the United States during 2026, including FDA clearances for key products within its interventional MR technology platform. With these approvals, the company is now positioned to commercialise its solutions across pediatric and adult cardiac care facilities in the U.S. market.
Imricor’s shares responded positively to the announcement, trading higher during the July 27, 2026 session following confirmation of the first commercial U.S. installation. The company’s stock has also recorded significant gains over the previous year as investors continue to track its progress toward commercial expansion.
The first hospital agreement provides Imricor with an important reference site as it seeks to introduce its technology to a wider healthcare market. The company is now focused on expanding hospital adoption, strengthening its commercial presence, and developing additional applications for magnetic resonance-guided interventions.
Imricor’s NorthStar System Brings Radiation-Free Cardiac Procedures Into U.S. Hospitals
The foundation of Imricor’s technology strategy is the development of medical devices that enable physicians to perform interventional procedures under real-time magnetic resonance imaging guidance. Traditional cardiac catheterisation procedures typically rely on X-ray fluoroscopy, which exposes both patients and healthcare professionals to ionising radiation.
The NorthStar system is designed to replace this approach by allowing physicians to perform cardiac interventions within an MR environment. According to Imricor, the technology provides detailed anatomical and functional information during procedures while eliminating radiation exposure associated with conventional imaging methods.
This capability is particularly significant in pediatric cardiology, where patients with congenital heart conditions may require multiple procedures throughout their lifetime. Reducing cumulative radiation exposure is considered an important clinical advantage for younger patients who may undergo repeated diagnostic and therapeutic interventions.
The NorthStar system is supported by Imricor’s broader portfolio of MR-compatible devices, including diagnostic and ablation catheters, steerable sheaths, and the Advantage-MR EP Recorder/Stimulator. Together, these products are designed to enable physicians to conduct a range of cardiac procedures within an interventional MR laboratory.
Rady Children’s Hospital plans to initially use the NorthStar platform for cardiac catheterisation procedures before expanding its applications to diagnostic electrophysiology and cardiac ablation procedures. The hospital’s broader vision is to create a comprehensive radiation-free cardiac intervention program.
The agreement also highlights the growing interest among healthcare institutions in technologies that combine improved imaging capabilities with safer procedural environments. Beyond reducing radiation exposure, MR-guided procedures may provide physicians with additional information related to soft tissue structures, blood flow, and cardiac function during interventions.
FDA Clearances Support Imricor’s Expansion Across Pediatric and Adult Cardiac Markets
The commercial launch of Imricor’s NorthStar system in the United States was enabled by several regulatory milestones achieved during 2026. Earlier in the year, the company received FDA 510(k) clearance for its Vision-MR Diagnostic Catheter, marking its first product clearance in the U.S. healthcare market.
The NorthStar Mapping System also received FDA clearance and was positioned by Imricor as the first three-dimensional mapping and guidance platform specifically developed for interventional magnetic resonance procedures.
In July 2026, the FDA expanded pediatric labeling for both NorthStar and the Vision-MR Diagnostic Catheter, allowing the systems to be used for patients across all age groups. The expanded approvals significantly increased Imricor’s commercial opportunity by enabling access to pediatric hospitals and broader cardiac care facilities.
The company estimates that the expanded indications provide potential access to more than 250 children’s hospitals and over 2,000 adult hospitals in the United States that perform cardiac catheterisation procedures.
Alongside its market expansion, Imricor has also established a new business division, Imricor Cardiovascular, focused specifically on cardiac catheterisation procedures under real-time MR guidance. The new vertical expands the company’s commercial focus beyond electrophysiology and ablation, creating additional opportunities within cardiovascular care.
The company believes the broader application of its technology could support future revenue growth through both capital equipment sales and recurring demand for disposable medical devices used during procedures.
The adoption of MR-guided cardiac procedures may also provide operational advantages for hospitals. Imricor has highlighted that combining imaging and catheterisation within a single MR-guided session could simplify workflows compared with traditional care pathways, where patients may require separate imaging and intervention appointments.
The company estimates that an integrated iMR workflow could reduce per-patient procedural time by approximately 35%, while potentially improving utilisation of existing hospital resources.
Following the Rady Children’s agreement, Imricor expects additional U.S. hospital purchases as several potential customers progress through purchasing processes. The company stated that expected revenue from upcoming NorthStar sales could exceed the total revenue generated from its European operations in 2025.
To support this expansion, Imricor is increasing its U.S. commercial workforce, including additional sales personnel focused on regional hospital engagement. The company plans to continue strengthening its presence as adoption of interventional MR technology develops.
The launch at Rady Children’s Hospital represents a significant step in bringing radiation-free cardiac intervention technology into mainstream clinical practice. As healthcare providers continue seeking safer and more advanced procedural approaches, Imricor’s NorthStar system could play an important role in shaping the future of cardiac imaging and intervention in the United States.
